Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR mutant Lung Cancer

Irreversible pyrimidine based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR activating and EGFR inhibitor resistant T790M mutations more potently than wild type EGFR. While this class of mutant selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGF...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Discov
Auteurs principaux: Tricker, Erin M., Xu, Chunxiao, Uddin, Sharmeen, Capelletti, Marzia, Ercan, Dalia, Ogino, Atsuko, Pratilas, Christine A., Rosen, Neal, Gray, Nathanael S., Wong, Kwok-Kin, Jänne, Pasi A.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824006/
https://ncbi.nlm.nih.gov/pubmed/26036643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0063
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires